{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Koehm M"],"funding":["Fraunhofer Cluster of Excellence for Immune-Mediated Diseases","Frauenhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany","Janssen Cilag","LOEWE Zentrum Translational Medicine and Pharmacology"],"pagination":["e003538"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10749014"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(4)"],"pubmed_abstract":["<h4>Background</h4>The influence of sex on treatment outcomes during interleukin-12/23 therapy in patients with psoriatic arthritis (PsA) has not been explored.<h4>Objective</h4>To conduct exploratory post hoc analyses of sex-stratified data from the MUST trial, an investigator-initiated, multicentre, phase 3b study in which patients with active PsA initiating treatment with open-label ustekinumab were randomised to treatment with placebo or methotrexate (MTX).<h4>Methods</h4>We evaluated baseline characteristics, key treatment outcomes and adverse events stratified by sex, with a focus on outcomes that did not include erythrocyte sedimentation rate (ESR) as a component due to the known elevation of ESR in females.<h4>Results</h4>A total of 166 patients were treated with ustekinumab+MTX (3"],"journal":["RMD open"],"pubmed_title":["Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial."],"pmcid":["PMC10749014"],"funding_grant_id":["Not applicable"],"pubmed_authors":["Brandt J","Demary W","Kellner H","Burmester GR","Braun J","Brandt-Jurgens J","Rech J","Schwenke H","Behrens F","Koehm M","Thiele A","Finzel S","Rubbert-Roth A","Wassenberg S","Foldenauer AC","Benesova K","Max R","Thaci D","Kofler D","Kiltz U","Sieburg M","Alten RH","Walter J","Kofler DM","Kastner P","Rossmanith T","Kruger K","Lorenz G","MUST Investigator Group","von Hinuber U","Bergner R","Kleye A","Poddubnyy D","Voll RE"],"additional_accession":[]},"is_claimable":false,"name":"Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial.","description":"<h4>Background</h4>The influence of sex on treatment outcomes during interleukin-12/23 therapy in patients with psoriatic arthritis (PsA) has not been explored.<h4>Objective</h4>To conduct exploratory post hoc analyses of sex-stratified data from the MUST trial, an investigator-initiated, multicentre, phase 3b study in which patients with active PsA initiating treatment with open-label ustekinumab were randomised to treatment with placebo or methotrexate (MTX).<h4>Methods</h4>We evaluated baseline characteristics, key treatment outcomes and adverse events stratified by sex, with a focus on outcomes that did not include erythrocyte sedimentation rate (ESR) as a component due to the known elevation of ESR in females.<h4>Results</h4>A total of 166 patients were treated with ustekinumab+MTX (3","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2026-07-15T01:18:04.508Z","creation":"2025-06-01T01:18:17.248Z"},"accession":"S-EPMC10749014","cross_references":{"pubmed":["38114198"],"doi":["10.1136/rmdopen-2023-003538"]}}